Kintor Pharmaceutical shares soared more than 11%
Kintor Pharmaceutical shares soared more than 11%
Shares of the Chinese drug developer-- $KINTOR PHARMA-B(09939.HK)$ increased 11.50% to 28.60 as at 10:50 am. $KINTOR PHARMA-B(09939.HK)$ surged over 170% in the last five trading days.
中國藥品開發商的股票--$金達醫藥-B(09939.HK)$截至上午10：50，漲幅為11.50%至28.60$金達醫藥-B(09939.HK)$在過去的五個交易日中，漲幅超過170%。
Kintor Pharma's Proxalutamide demonstrated a reduction in hospitalization/mortality for patients with mild to moderate COVID-19 in Phase III MRCT study.
在第三階段的MRCT研究中，Kintor Pharma公司的普羅沙魯胺顯示輕中度新冠肺炎患者的住院率/死亡率降低。
●Proxalutamide demonstrates a significant reduction in hospitalization/death rate with a protection rate reaching 100% for patients treated more than seven days (p
●普羅沙魯胺顯著降低住院/死亡率，治療超過7天的患者保護率達到100%(p
● Proxalutamide reduced risk of hospitalization or death especially in those with high-risk factors.
●普羅沙魯胺降低了住院或死亡的風險，特別是在那些具有高危因素的患者。
● Proxalutamide demonstrates significant reduction in COVID-19 viral load and improved coronavirus-related symptoms.
●丙沙魯胺顯示出新冠肺炎病毒載量的顯著降低和冠狀病毒相關症狀的改善。
● The Phase III multi-regional clinical trial (MRCT) enrolled 99% of patients in multiple centers accross the United States.
●第三階段多區域臨牀試驗在美國的多箇中心招募了99%的患者。